TOPADUR Pharma AG is a clinical-stage swiss biopharmaceutical start-up based in Schlieren, Zurich.
We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.
The company has discovered the DualTOP™ technology platform consisting of new dual-acting drugs.
We developed an attractive portfolio of drug candidates to address high unmet needs in aging diseases.
Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, age-related macula degeneration, diabetic retinopathy, colorectal cancer, hair loss and skin aging.
TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.Read more
Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.Read more
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.Read more